Get the Stockscreener App
21.30
1.38%
0.29
Syndax Pharmaceuticals Inc stock is traded at $21.30, with a volume of 1.10M.
It is up +1.38% in the last 24 hours and up +13.36% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$21.01
Open:
$21.08
24h Volume:
1.10M
Relative Volume:
0.44
Market Cap:
$1.85B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-7.1959
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+0.00%
1M Performance:
+13.36%
6M Performance:
+136.67%
1Y Performance:
+51.28%
1-Day Range:
$20.81
$21.34
1-Week Range:
$20.42
$21.41
52-Week Range:
$8.58
$22.73
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
21.30 | 1.83B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded at Wall Street Zen - MarketBeat
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
Commit To Buy Syndax Pharmaceuticals At $13, Earn 21.5% Using Options - Nasdaq
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Debt Sensibly? - 富途牛牛
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year HighTime to Buy? - MarketBeat
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
SNDX (Syndax Pharmaceuticals) EV-to-OCF : -4.35 (As of Dec. 21, 2025) - GuruFocus
Why Syndax Pharmaceuticals Inc. stock could outperform in 2025Earnings Trend Report & Daily Price Action Insights - Bölüm Sonu Canavarı
Syndax Pharmaceuticals (STU:1T3) EV-to-OCF : -4.13 (As of Dec. 21, 2025) - GuruFocus
Syndax Pharmaceuticals modernizes bylaws for electronic share issuance - MSN
How Syndax Pharmaceuticals Inc. stock reacts to inflationary pressures2025 Volatility Report & AI Enhanced Trading Alerts - Bölüm Sonu Canavarı
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance - TipRanks
Published on: 2025-12-19 14:41:17 - DonanımHaber
Assenagon Asset Management S.A. Sells 255,848 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. stock outperform Nasdaq indexEarnings Trend Report & Real-Time Market Trend Scan - DonanımHaber
Will Syndax Pharmaceuticals Inc. stock beat EPS estimates2025 Market Overview & Community Trade Idea Sharing - ulpravda.ru
Syndax Pharmaceuticals (STU:1T3) EV-to-OCF : -3.99 (As of Dec. 19, 2025) - GuruFocus
How currency fluctuations impact Syndax Pharmaceuticals Inc. stock2025 Market Sentiment & Safe Capital Allocation Plans - ulpravda.ru
Syndax Pharma: Continuing Execution In AML (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week HighWhat's Next? - MarketBeat
Can Revuforj’s Awards Momentum Redefine Syndax Pharmaceuticals’ (SNDX) Precision Oncology Investment Narrative? - Sahm
Syndax Pharmaceuticals stock hits 52-week high at $21.27 By Investing.com - Investing.com Canada
Hudson Bay Capital Management LP Has $4.15 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Earnings Notes - Trefis
Syndax Pharmaceuticals (FRA:1T3) OCF Margin % : -153.77% (As of Sep. 2025) - GuruFocus
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Syndax Pharmaceuticals' Revuforj® Recognized as Best New Drug at 2025 Scrip Awards - Quiver Quantitative
Syndax (Nasdaq: SNDX) wins Scrip 2025 Best New Drug for FDA-approved Revuforj - Stock Titan
(SNDX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentCandlestick Pattern Analysis & Rapid Portfolio Expansion - earlytimes.in
Jump Financial LLC Makes New $3.57 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week HighHere's Why - MarketBeat
Syndax Pharmaceuticals (SNDX) Valuation After Strong New Revuforj Data at Major Hematology Meeting - Sahm
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Stempoint Capital LP - MarketBeat
Hsbc Holdings PLC Boosts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG Research - MarketBeat
SNDX: BTIG Reiterates "Buy" Rating with Price Target of $56 | SN - GuruFocus
TD Cowen reiterates Buy rating on Syndax Pharmaceuticals stock By Investing.com - Investing.com Canada
Syndax Pharmaceuticals (SNDX): Valuation Check After Positive Revuforj Data at the 67th ASH Meeting - Yahoo Finance
Is Syndax Pharmaceuticals Fairly Priced After Recent Oncology Pipeline Momentum? - Yahoo Finance
Transcript : Syndax Pharmaceuticals, Inc. Presents at The 67th American Society of Hematology Annual Meeting, Dec-08-2025 07 - marketscreener.com
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum - The Manila Times
Syndax Pharmaceuticals Highlights Promising Efficacy and Safety Data for Revuforj® at the 67th ASH Annual Meeting - Quiver Quantitative
Syndax Highlights Leadership in Menin Inhibition at ASH - GlobeNewswire
Syndax (Nasdaq: SNDX) posts 92% CRc in Phase 1 revumenib AML combo data at ASH 2025 - Stock Titan
Schroder Investment Management Group Buys 64,598 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Tema Etfs LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Syndax Pharmaceuticals stock hits 52-week high at 20.25 USD By Investing.com - Investing.com Australia
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):